Medicus Pharma Ltd. (MDCX) intrinsic value & 10-year financials
Medicus Pharma Ltd. (MDCX) has no Graham intrinsic value right now because the formula needs positive earnings.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $3.25
- Market cap
- $56.2M
- Revenue (FY2025)
- —
- ROIC (10-yr avg)
- 1020.2%
- Free cash flow (FY2025)
- —
MDCX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | — | -$47.3M | -$2.74 | — | — | 720.6% |
| FY2024 | — | -$11.2M | -$1.16 | — | — | 1562.1% |
| FY2023 | — | -$5.3M | -$1.53 | — | — | 778.1% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Medicus Pharma Ltd. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Medicus Pharma Ltd. returns on capital have been average, hovering around 10.2% ROIC over the decade.
Medicus Pharma Ltd. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Medicus Pharma Ltd. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.